These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 34625464

  • 1. The Cannabinoid Receptor Type 1 Positive Allosteric Modulator ZCZ011 Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice.
    Dodu JC, Moncayo RK, Damaj MI, Schlosburg JE, Akbarali HI, O'Brien LD, Kendall DA, Wu Z, Lu D, Lichtman AH.
    J Pharmacol Exp Ther; 2022 Jan; 380(1):1-14. PubMed ID: 34625464
    [Abstract] [Full Text] [Related]

  • 2. CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.
    Trexler KR, Eckard ML, Kinsey SG.
    Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
    [Abstract] [Full Text] [Related]

  • 3. Effects of CB1 receptor negative allosteric modulator Org27569 on oxycodone withdrawal symptoms in mice.
    Scicluna RL, Everett NA, Badolato CJ, Wilson BB, Bowen MT.
    Psychopharmacology (Berl); 2024 Aug; 241(8):1705-1717. PubMed ID: 38676755
    [Abstract] [Full Text] [Related]

  • 4. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
    Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, Long JZ, Nomura DK, Sim-Selley LJ, Cravatt BF, Akbarali HI, Lichtman AH.
    J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
    [Abstract] [Full Text] [Related]

  • 5. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH, Sheikh SM, Loh HH, Martin BR.
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [Abstract] [Full Text] [Related]

  • 6. A Cannabinoid CB1 Receptor-Positive Allosteric Modulator Reduces Neuropathic Pain in the Mouse with No Psychoactive Effects.
    Ignatowska-Jankowska BM, Baillie GL, Kinsey S, Crowe M, Ghosh S, Owens RA, Damaj IM, Poklis J, Wiley JL, Zanda M, Zanato C, Greig IR, Lichtman AH, Ross RA.
    Neuropsychopharmacology; 2015 Dec; 40(13):2948-59. PubMed ID: 26052038
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception.
    Iyer V, Saberi SA, Pacheco R, Sizemore EF, Stockman S, Kulkarni A, Cantwell L, Thakur GA, Hohmann AG.
    Neuropharmacology; 2024 Oct 01; 257():110052. PubMed ID: 38936657
    [Abstract] [Full Text] [Related]

  • 9. Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice.
    Ramesh D, Gamage TF, Vanuytsel T, Owens RA, Abdullah RA, Niphakis MJ, Shea-Donohue T, Cravatt BF, Lichtman AH.
    Neuropsychopharmacology; 2013 May 01; 38(6):1039-49. PubMed ID: 23303065
    [Abstract] [Full Text] [Related]

  • 10. Endothelin ETA receptor antagonist reverses naloxone-precipitated opioid withdrawal in mice.
    Bhalla S, Pais G, Tapia M, Gulati A.
    Can J Physiol Pharmacol; 2015 Nov 01; 93(11):935-44. PubMed ID: 26440527
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
    Deng L, Guindon J, Cornett BL, Makriyannis A, Mackie K, Hohmann AG.
    Biol Psychiatry; 2015 Mar 01; 77(5):475-87. PubMed ID: 24853387
    [Abstract] [Full Text] [Related]

  • 13. Validation and characterization of oxycodone physical dependence in C57BL/6J mice.
    Carper M, Contreras KM, Walentiny DM, Beardsley PM, Damaj MI.
    Eur J Pharmacol; 2021 Jul 15; 903():174111. PubMed ID: 33901461
    [Abstract] [Full Text] [Related]

  • 14. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
    Yamaguchi T, Hagiwara Y, Tanaka H, Sugiura T, Waku K, Shoyama Y, Watanabe S, Yamamoto T.
    Brain Res; 2001 Aug 03; 909(1-2):121-6. PubMed ID: 11478928
    [Abstract] [Full Text] [Related]

  • 15. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward.
    Slivicki RA, Iyer V, Mali SS, Garai S, Thakur GA, Crystal JD, Hohmann AG.
    Front Mol Neurosci; 2020 Aug 03; 13():54. PubMed ID: 32410959
    [Abstract] [Full Text] [Related]

  • 16. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.
    Neuropharmacology; 2019 Jun 03; 151():1-12. PubMed ID: 30940536
    [Abstract] [Full Text] [Related]

  • 17. Cannabidiol Reduced the Severity of Gastrointestinal Symptoms of Opioid Withdrawal in Male and Female Mice.
    Scicluna RL, Wilson BB, Thelaus SH, Arnold JC, McGregor IS, Bowen MT.
    Cannabis Cannabinoid Res; 2024 Apr 03; 9(2):547-560. PubMed ID: 36577048
    [Abstract] [Full Text] [Related]

  • 18. Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.
    Mori T, Komiya S, Uzawa N, Inoue K, Itoh T, Aoki S, Shibasaki M, Suzuki T.
    Eur J Pharmacol; 2013 Sep 05; 715(1-3):238-45. PubMed ID: 23707904
    [Abstract] [Full Text] [Related]

  • 19. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
    Zhang G, Wu X, Zhang YM, Liu H, Jiang Q, Pang G, Tao X, Dong L, Stackman RW.
    Neuropharmacology; 2016 Feb 05; 101():246-54. PubMed ID: 26432939
    [Abstract] [Full Text] [Related]

  • 20. Physiological dependence to mitragynine indicated by a rapid cross-dependence procedure with heroin-dependent mice.
    Yue K, Katz JL, Shu X.
    Psychopharmacology (Berl); 2022 Mar 05; 239(3):897-908. PubMed ID: 35107609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.